• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者残疾和临床数据在多发性硬化症中的有效性。

Validity of patient-derived disability and clinical data in multiple sclerosis.

机构信息

Department of Neurology, University Hospital of Wales, Cardiff, UK.

出版信息

Mult Scler. 2010 Apr;16(4):472-9. doi: 10.1177/1352458509358902. Epub 2010 Feb 11.

DOI:10.1177/1352458509358902
PMID:20150395
Abstract

Patient-derived historical data are widely employed to make fundamental management decisions in multiple sclerosis, although the validity of the information provided is unclear. The objectives of this study were to determine validity of patient-derived historical data and to describe the utility of a locally relevant, patient-administered questionnaire designed to ascertain current disability and other important disease milestones. A well-described cohort of 99 patients was identified for whom comparable, detailed, prospective longitudinal clinician-derived data were available. Patient-derived data were collected by completion of a standardized questionnaire or telephone interview for comparison. Reliability analysis for current Expanded Disability Status Scale (EDSS) demonstrated an intraclass correlation coefficient of 0.79 between questionnaire and clinician-derived data in 79 patients, with complete agreement in 75.9%. Intraclass correlation coefficient for year of disease onset, diagnosis and onset of secondary progression was 0.86, 0.91 and 0.78, respectively. Time to EDSS >4.0, 6.0 and 8.0 all had an intraclass correlation coefficient of >0.9. Less robust agreement was observed for current disease course (Kappa coefficient 0.71), initial relapse rate (intraclass correlation coefficient 0.37) and clinical features at disease onset (Kappa 0.25). We conclude that self-reported questionnaires can provide reliable current and retrospective data on time-to-disability milestones with high levels of correlation observed for some additional elements, supporting the use of selected components of patient-derived data in clinical practice and for epidemiological studies.

摘要

患者提供的历史数据在多发性硬化症的基本管理决策中被广泛应用,尽管其提供信息的有效性尚不清楚。本研究的目的是确定患者提供的历史数据的有效性,并描述一种局部相关的、由患者管理的问卷的实用性,该问卷旨在确定当前残疾和其他重要疾病里程碑。确定了一个具有良好描述性的 99 名患者队列,他们具有可比的、详细的、前瞻性纵向临床医生提供的数据。通过完成标准化问卷或电话访谈来收集患者提供的数据以进行比较。对当前扩展残疾状况量表(EDSS)的可靠性分析表明,在 79 名患者中,问卷和临床医生提供的数据之间的组内相关系数为 0.79,完全一致的比例为 75.9%。疾病发病年份、诊断和继发进展发病年份的组内相关系数分别为 0.86、0.91 和 0.78。EDSS >4.0、6.0 和 8.0 的时间均具有 >0.9 的组内相关系数。当前疾病进程(Kappa 系数 0.71)、初始复发率(组内相关系数 0.37)和疾病发病时的临床特征(Kappa 0.25)的一致性较弱。我们得出结论,自我报告问卷可以提供可靠的当前和回顾性数据,用于残疾里程碑的时间,一些额外元素的相关性较高,这支持在临床实践和流行病学研究中使用患者提供数据的选定部分。

相似文献

1
Validity of patient-derived disability and clinical data in multiple sclerosis.患者残疾和临床数据在多发性硬化症中的有效性。
Mult Scler. 2010 Apr;16(4):472-9. doi: 10.1177/1352458509358902. Epub 2010 Feb 11.
2
Natural history of multiple sclerosis: a unifying concept.多发性硬化症的自然史:一个统一的概念。
Brain. 2006 Mar;129(Pt 3):606-16. doi: 10.1093/brain/awl007. Epub 2006 Jan 16.
3
Long-term follow-up of benign multiple sclerosis in Hordaland County, Western Norway.挪威西部霍达兰郡良性多发性硬化症的长期随访
Mult Scler. 2009 Aug;15(8):942-50. doi: 10.1177/1352458509106511. Epub 2009 Jul 1.
4
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?疾病修正药物在延缓复发型多发性硬化症进展方面的效果如何?
Neurology. 2007 Oct 9;69(15):1498-507. doi: 10.1212/01.wnl.0000271884.11129.f3. Epub 2007 Aug 15.
5
Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.扩展残疾状态量表(EDSS)和多发性硬化功能综合评分(MSFC)在原发性进行性多发性硬化中的反应性和预测价值。
Neurology. 2008 Mar 25;70(13 Pt 2):1084-91. doi: 10.1212/01.wnl.0000288179.86056.e1. Epub 2008 Jan 9.
6
Predictors of relapse rate in MS clinical trials.多发性硬化症临床试验中复发率的预测因素。
Neurology. 2005 Dec 13;65(11):1769-73. doi: 10.1212/01.wnl.0000187122.71735.1f.
7
Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.复发缓解型多发性硬化轻度残疾患者的认知障碍及其与疾病指标的关系:多发性硬化认知障碍(COGIMUS)研究的基线结果
Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.
8
The natural history of primary progressive MS in British Columbia, Canada.加拿大不列颠哥伦比亚省原发性进行性多发性硬化症的自然病史。
Neurology. 2005 Dec 27;65(12):1919-23. doi: 10.1212/01.wnl.0000188880.17038.1d.
9
ADC measurements in various patterns of multiple sclerosis lesions.多发性硬化症病变不同模式下的表观扩散系数测量
J Med Assoc Thai. 2006 Feb;89(2):196-204.
10
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.原发进展型与复发缓解型多发性硬化症:脑脊液寡克隆 IgM 的存在及其预后价值。
Mult Scler. 2011 Mar;17(3):303-11. doi: 10.1177/1352458510386996. Epub 2010 Nov 15.

引用本文的文献

1
Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes.组合蛋白生物标志物可预测多发性硬化症的诊断和结局。
J Neuroinflammation. 2024 Feb 17;21(1):52. doi: 10.1186/s12974-024-03036-4.
2
Characterizing Long-term Disability Progression and Employment in NARCOMS Registry Participants with Multiple Sclerosis Taking Dimethyl Fumarate.对接受富马酸二甲酯治疗的多发性硬化症NARCOMS注册参与者的长期残疾进展和就业情况进行特征分析。
Int J MS Care. 2021 Nov-Dec;23(6):239-244. doi: 10.7224/1537-2073.2020-109. Epub 2021 Jul 9.
3
A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod.
富马酸二甲酯或芬戈莫德治疗的多发性硬化症患者长期残疾恶化的倾向匹配比较。
Ther Adv Neurol Disord. 2021 Jun 30;14:17562864211021177. doi: 10.1177/17562864211021177. eCollection 2021.
4
Distinct clinical phenotypes for Crohn's disease derived from patient surveys.通过患者调查得出的克罗恩病不同临床表型。
BMC Gastroenterol. 2021 Apr 9;21(1):160. doi: 10.1186/s12876-021-01740-6.
5
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.初始疾病修饰治疗与随后继发进展性多发性硬化转化的相关性。
JAMA. 2019 Jan 15;321(2):175-187. doi: 10.1001/jama.2018.20588.
6
How common is truly benign MS in a UK population?在英国人群中,真正良性的多发性硬化症有多常见?
J Neurol Neurosurg Psychiatry. 2019 May;90(5):522-528. doi: 10.1136/jnnp-2018-318802. Epub 2018 Sep 3.
7
Telemedicine for Monitoring MS Activity and Progression.用于监测多发性硬化症活动和进展的远程医疗
Curr Treat Options Neurol. 2015 Nov;17(11):47. doi: 10.1007/s11940-015-0377-y.
8
'You are just left to get on with it': qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis.“你只能继续应对下去”:关于患者及照料者向继发进展型多发性硬化症转变经历的定性研究
BMJ Open. 2015 Jul 22;5(7):e007674. doi: 10.1136/bmjopen-2015-007674.
9
Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet.具有临床意义的疲劳:通过互联网招募的国际多发性硬化症成年患者样本中的患病率及相关因素
PLoS One. 2015 Feb 18;10(2):e0115541. doi: 10.1371/journal.pone.0115541. eCollection 2015.
10
A pilot study on factors involved with work participation in the early stages of multiple sclerosis.一项关于多发性硬化症早期工作参与相关因素的试点研究。
PLoS One. 2014 Aug 25;9(8):e105673. doi: 10.1371/journal.pone.0105673. eCollection 2014.